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Introduction: We investigated the clinical and serological features of patients with antineutrophil cytoplasmic
antibody (ANCA)-associated vasculitis (AAV) in Japan using data from a nationwide, prospective, inception cohort study.
Methods: In total, 156 Japanese patients with newly diagnosed AAV were classified according to the European
Medicines Agency (EMEA) algorithm with exploratory surrogate markers for AAV-related non-granulomatous pulmonary
lesions, predefined as alveolar haemorrhage and interstitial lung disease (ILD), and their clinical and serological features
were evaluated.
Results: Using the EMEA algorithm, we identified 14 patients (9.0%) with eosinophilic granulomatosis with polyangiitis
(EGPA), 33 (21.2%) with granulomatosis with polyangiitis (GPA), 78 (50.0%) with microscopic polyangiitis and
renal-limited vasculitis (MPA/RLV), and 31 (19.9%) with unclassifiable vasculitis. The average ages of patients with EGPA
(male/female, 5/9), GPA (12/21), and MPA/RLV (35/43) and unclassifiable (9/22) were 58.0, 63.6, 71.1, and 70.6 years,
respectively. Myeloperoxidase (MPO)-ANCA and proteinase-3 ANCA positivity was 50.0% and 0% for EGPA, 54.6% and
45.5% for GPA, 97.4% and 2.6% for MPA/RLV, and 93.5% and 3.2% for unclassifiable, respectively. According to the
Birmingham Vasculitis Activity Score (BVAS), cutaneous (71.4%) and nervous system (92.9%) manifestations were
prominent in EGPA and ear, nose, and throat manifestations (84.9%) and chest manifestations (66.7%) in GPA. Renal
manifestations developed frequently in MPA/RLV (91.0%) and GPA (63.6%). The average serum creatinine levels were
0.71 mg/dL for EGPA, 1.51 mg/dL for GPA, 2.46 mg/dL for MPA/RLV, and 0.69 mg/dL for unclassifiable. The percentages
of patients with ILD were 14.3% for EGPA, 9.0% for GPA, 47.4% for MPA/RLV, and 61.3% for unclassifiable. Patients with
ILD (n = 61) had significantly lower BVAS (P = 0.019) with fewer ear, nose, and throat and cardiovascular manifestations
than patients without ILD (n = 95).
Conclusions: MPO-ANCA-positive MPA/RLV is the most common form of AAV in Japanese patients, and one-half of
patients with GPA were positive for MPO-ANCA. ILD is an important clinical manifestation in Japanese patients with
AAV. Unclassifiable vasculitis with MPO-ANCA positivity and ILD may represent a novel variant of MPA.
Trial Registration: The University Hospital Medical Information Network Clinical Trials Registry: UMIN000001648.
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Microscopic polyangiitis (MPA), granulomatosis with po-
lyangiitis (Wegener’s granulomatosis) (GPA), and eosi-
nophilic granulomatosis with polyangiitis (Churg–Strauss
syndrome) (EGPA) are the major categories of antineutro-
phil cytoplasmic antibody (ANCA)-associated vasculitis
(AAV), a multisystem autoimmune disease characterised
by ANCA production and small-vessel inflammation [1,2].
Despite the overlapping clinicopathologic characteristics
between the component diseases, the disease evolution,
organ involvement, prognosis, and other clinical charac-
teristics differ substantially among them. In addition, there
are interesting geographic and ethnic differences in their
relative incidence and myeloperoxidase (MPO)-ANCA or
proteinase-3 (PR3)-ANCA positivity [3].
In 2007 Watts and colleagues proposed an AAV classifi-
cation algorithm, the European Medicines Agency (EMEA)
algorithm, with consensus of a group of European phy-
sicians interested in the epidemiology of vasculitis [4].
This stepwise algorithm incorporated both the American
College of Rheumatology (ACR) criteria for EGPA and
GPA and the Chapel Hill Consensus Conference (CHCC)
definition of EGPA, GPA, and MPA [2]. In the EMEA al-
gorithm, surrogate markers of granulomatous inflamma-
tion for GPA and those of renal vasculitis for renal-limited
vasculitis (RLV), an organ-limited variant of MPA, were
defined [4]. This algorithm is useful for classifying patients
with AAV because no overlapping diagnoses occur and
fewer patients are considered to have unclassifiable vascu-
litis [5], and has been used as the standard method for
classification of AAV diseases in recent studies [6,7].
Only two reports have validated the algorithm in other
ethnicities outside Europe using a good-quality database.
Studies from China [5] and Japan [3] applied the EMEA
algorithm to their patient populations and found that
MPO-ANCA-positive MPA was the most common form
of AAV. These studies, however, were retrospective and
evaluated clinical data of patients from a small number
of hospitals.
The lung is one of the organs frequently involved in
AAV, and pulmonary granuloma, alveolar haemorrhage,
and interstitial lung disease (ILD) are representative pul-
monary lesions. Among these, only pulmonary granu-
loma is included in the EMEA algorithm. ILD in AAV is
associated with MPO-ANCA and is more common in
Asian countries [8-10] than in western countries [11,12],
and some patients with MPO-ANCA and ILD subse-
quently develop typical MPA [13]. To understand the
nature of AAV and classify the disease from a global per-
spective, it is essential to more precisely delineate the
clinical implications of ILD in AAV in Asian countries.
To characterise the clinical and laboratory features,
effectiveness, and safety of the remission-induction ther-
apy used, as well as the prognosis of Japanese patientswith AAV, the Research Committee on Intractable Vascu-
litides of the Ministry of Health, Labour and Welfare of
Japan implemented a nationwide prospective cohort study
of Remission Induction Therapy in Japanese Patients with
ANCA-associated Vasculitides (RemIT-JAV). In this study,
we classified Japanese patients with newly diagnosed AAV
enrolled in the RemIT-JAV study according to the EMEA
algorithm and compared their phenotypes across the
AAVs. We also investigated the clinical relevance of ILD
in the patient population.
Methods
Database
Twenty-two tertiary care institutions (university hospi-
tals and referring hospitals) participated in this study
(See Appendix) and enrolled consecutive patients with
newly diagnosed AAV from April 2009 to December
2010. The criteria for enrolment in this study included
receiving a diagnosis of AAV from the site investigators,
fulfilling the criteria for primary systemic vasculitis pro-
posed by the EMEA algorithm [4], and requiring im-
munosuppressive treatment based on the discretion of
the site investigators. The exclusion criteria were age
younger than 20 years, recurrent AAV, serological evi-
dence for hepatitis B virus or hepatitis C virus infection,
and a history of malignancies because this may influence
treatment selection and prognosis of patients with AAV.
We conducted this study according to the Declaration of
Helsinki and the Ethical Guidelines for Epidemiological
Research in Japan. Written informed consent was ob-
tained from each participant, and the study protocol was
approved by the ethics committee at each participating
hospital (refer to Acknowledgements). This study was
registered with the University Hospital Medical Informa-
tion Network Clinical Trials Registry (UMIN000001648).
Data collection
Each patient’s baseline data included demographic infor-
mation, general performance categorised using scales of
the World Health Organization performance status except
category 5 (death) [14], comorbidities, laboratory data, dis-
ease activity scored using the Birmingham Vasculitis Ac-
tivity Score (BVAS) 2003 [15], imaging data (for example,
chest radiograph, thoracic computed tomography, and
magnetic resonance imaging of the head), and respiratory
function data. The World Health Organization perform-
ance status runs from 0 to 5, with 0 denoting perfect
health and 5 denoting death (0, asymptomatic; 1, symp-
tomatic but completely ambulatory; 2, symptomatic, <50%
in bed during the day; 3, symptomatic, >50% in bed, but
not bedbound; 4, bedbound; 5, death).
Patients were evaluated at months 3, 6, 12, 18, and 24
and at relapse, and the following data were collected:
vital status, BVAS 2003, laboratory data, treatments, and
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corded at months 6, 12, and 24. Chest radiography, thor-
acic computed tomography, arterial blood gas analysis,
and respiratory function data were collected at months 12
and 24 in patients with pulmonary involvement. Observa-
tion was completed in March 2013. Only the baseline data
are included in this study; the results from analyses of
follow-up data will be reported separately.
The site investigators completed and sent the electronic
case report form for each patient to the RemIT-JAV data
centre at the Department of Medicine and Clinical Sci-
ence, Okayama University Graduate School of Medicine,
Dentistry and Pharmaceutical Sciences, Okayama, Japan.
EMEA classification algorithm for AAV
The enrolled patients were classified using the stepwise
EMEA algorithm as described previously [2,4]. Briefly, the
ACR criteria and Lanham criteria for EGPA were applied
first. Patients who did not fulfil the criteria for EGPA were
classified as having GPA if they met the ACR criteria for
GPA or the CHCC histological definition for GPA or if
they showed histology compatible with the CHCC defin-
ition for MPA or ANCA positivity with either of the
EMEA-defined GPA surrogate markers. The remaining
patients were classified as having MPA if they had clinical
features and histology compatible with small-vessel vascu-
litis without the GPA surrogate markers. In addition,
ANCA-positive patients who had the EMEA-defined sur-
rogate markers for renal vasculitis were classified as hav-
ing RLV, a variant form of MPA. The rest of the patients
without histology compatible with the CHCC definition of
classic polyarteritis nodosa or typical angiographic features
of classic polyarteritis nodosa were categorised as having
unclassifiable vasculitis.
To identify a subset of unclassifiable vasculitis with
AAV-related nongranulomatous pulmonary lesions, we
defined exploratory surrogate markers for alveolar haemor-
rhage and ILD and then applied them to the EMEA-
defined unclassifiable patient population. Surrogate markers
for these conditions were as follows: haemoptysis or alveo-
lar haemorrhage evaluated by bronchoscopic examination;
or ILD diagnosed by chest X-ray or thoracic computed
tomography.
Disease severity
The disease severity of the enrolled patients was classified
as localised, early systemic, generalised, or severe according
to the European League Against Rheumatism recommen-
dation for conducting a clinical study in systemic vasculitis
[16]. Organ failure, classified as severe disease, was defined
by the presence of any of the following BVAS manifesta-
tions: massive haemoptysis/alveolar haemorrhage, respira-
tory failure, congestive cardiac failure, ischaemic abdominal
pain, or stroke. Threatened vital organ function,classified as generalised disease, was defined by the pres-
ence of any of the following BVAS manifestations: sudden
visual loss, blurred vision, retinal changes (vasculitis/
thrombosis/exudates/haemorrhage), conductive deafness,
sensorineural hearing loss, ischaemic cardiac pain, cardio-
myopathy, peritonitis, bloody diarrhoea, meningitis, or-
ganic confusion, seizures, cord lesion, cranial nerve palsy,
sensory peripheral neuropathy, or motor mononeuritis
multiplex. Serum creatinine levels were also used to
classify disease severity as localised and early systemic
(<120 μmol/l (1.3 mg/dl)), generalised (<500 μmol/l
(5.5 mg/dl)), and severe (≥500 μmol/l (5.5 mg/dl)) [16].
Statistical analysis
We used the baseline data of the patients enrolled in this
study for statistical analysis. The primary purpose of this
analysis was to determine the demographic and clinical
characteristics of Japanese patients with AAV. Categor-
ical variables were compared using Fisher’s direct prob-
ability test, and continuous variables were compared
using Student t test or the Mann–Whitney U test de-
pending on data distribution. P < 0.05 was considered
significant for statistical analyses between two categories.
When comparing among three categories, statistical sig-
nificance was determined by P < 0.05/3 using Bonferroni
correction to avoid multiplicity. All statistical analyses
were performed by a biostatistician using the Statistical
Package of JMP for Windows software (version 8.0.2;
SAS Institute Inc., Cary, NC, USA).
Results
Classification of 156 Japanese patients with AAV
according to the EMEA algorithm
In total, 159 patients with AAV were initially enrolled in
the RemIT-JAV study. Three patients were then excluded;
two patients did not undergo treatment, and one patient
had been diagnosed as having AAV and experienced a re-
lapse at the time of enrolment. As a result, 156 patients
with newly diagnosed AAV were enrolled in the study.
Using the EMEA algorithm, we identified 14 patients
with EGPA, 33 patients with GPA, 78 patients with MPA/
RLV, and 31 patients who were unclassifiable (Figure 1).
The average ages of the patients with EGPA (male/female,
5/9), GPA (male/female, 12/21), and MPA/RLV (male/
female, 35/43) were 58.0, 63.6, and 71.1 years, respectively
(Table 1). Patients with MPA/RLV were significantly older
at the time of presentation than those with EGPA and
GPA (P < 0.017 for both), and there was a female predom-
inance for all AAV diseases. MPO-ANCA was detectable
in 50.0% of patients with EGPA, in 54.6% of those with
GPA, and in 97.4% of those with MPA/RLV. In contrast,
PR3-ANCA was detectable in none of the patients with
EGPA, in 45.5% of those with GPA, and in 2.6% of those
with MPA/RLV.
Figure 1 Classification of patients with antineutrophil cytoplasmic antibody-associated vasculitis according to the EMEA algorithm in
this cohort study. AAV, antineutrophil cytoplasmic antibody-associated vasculitis; ACR, American College of Rheumatology; ANCA, antineutrophil
cytoplasmic antibody; EGPA, eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome); EMEA, European Medicines Agency; GPA,
granulomatosis with polyangiitis (Wegener’s granulomatosis); MPA, microscopic polyangiitis; RLV, renal-limited vasculitis; RV, renal vasculitis.
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to the EMEA algorithm
Of the patients classified with GPA, 22 patients fulfilled
the ACR criteria, two patients showed CHCC-defined
GPA histology, three patients showed CHCC-definedTable 1 Comparison of demographics and disease states amo
EGPA GP
(n = 14) (n
Male/female 5/9 12
Mean (median) age (years)a,c 58.0 ± 16.9 (62) 63
MPO-ANCAa,c 7 (50.0) 18
PR3-ANCAb,c 0 (0) 15
ANCA-negativea,b 7 (50.0) 3 (
Serum creatinine (mg/dl)a 0.71 ± 0.39 1.5
Disease severityc
Localised 0 (0) 4 (
Early systemic 1 (7.1) 5 (
Generalised 13 (92.9) 18




Interstitial lung diseasea 2 (14.3) 3 (
Alveolar haemorrhage 0 (0) 2 (
Values expressed as mean ± standard deviation or number (percentage) unless othe
ANCA, antineutrophil cytoplasmic antibody; EGPA, eosinophilic granulomatosis with
(Wegener’s granulomatosis); MPA, microscopic polyangiitis; MPO, myeloperoxidase;
GPA, and MPV/RLV groups were made by Student t test or Mann–Whitney U test. S
aEGPA versus MPA/RLV, bEGPA versus GPA, cGPA versus MPA/RLV. Unclassifiable AA
categorised according to the World Health Organization performance status exceptMPA histology in the presence of EMEA-defined GPA
surrogate markers, and six patients were positive for
ANCA in the presence of GPA surrogate markers. Con-
sequently, nine patients were classified by the presence
of GPA surrogate markers, mostly by the presence ofng AAV diseases
A MPA/RLV Unclassifiable
= 33) (n = 78) (n = 31)
/21 35/43 9/22
.6 ± 12.6 (61) 71.1 ± 10.0 (73) 70.6 ± 11.8 (73)
(54.6) 76 (97.4) 29 (93.5)
(45.5) 2 (2.6) 1 (3.2)
9.1) 1 (1.3) 2 (6.5)
1 ± 1.32 2.46 ± 2.18 0.69 ± 0.23
12.1) 0 (0) 0 (0)
15.1) 15 (19.2) 15 (48.4)
(54.6) 47 (60.3) 13 (41.9)
18.2) 16 (20.5) 3 (9.7)
11/2/11/1 10/29/17/16/6 3/11/7/9/1
9.0) 37 (47.4) 19 (61.3)
6.1) 9 (11.5) 2 (6.5)
rwise noted. AAV, antineutrophil cytoplasmic antibody-associated vasculitis;
polyangiitis (Churg–Strauss syndrome); GPA, granulomatosis with polyangiitis
PR3, proteinase-3; RLV, renal-limited vasculitis. Comparisons between the EGPA,
tatistical significance was determined by P < 0.05/3 using Bonferroni correction:
V was not compared with other forms of AAV. dGeneral performance was
category 5 (death).
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classified with MPA/RLV, 45 patients showed histology
compatible with small-vessel vasculitis without GPA sur-
rogate markers and 33 patients were positive for ANCA
with EMEA-defined surrogate markers for renal vasculitis.
Three patients with allergic rhinitis, but not asthma, who
had eosinophilia of peripheral blood and tissue were con-
sidered to have unclassifiable vasculitis. The eosinophilic
vasculitis was confirmed histologically in all three patients,
and two of these three patients were MPO-ANCA-
positive. The exploratory surrogate markers for AAV-
related nongranulomatous pulmonary lesions were positive
in 16 of the 31 unclassifiable patients; three patients had
both markers (alveolar haemorrhage and ILD), and 13 pa-
tients had only ILD. These 16 patients were all positive for
MPO-ANCA.Organ involvement of 156 Japanese patients with AAV
Patterns of organ involvement defined by the BVAS
2003 scoring system were described and compared
among patients with EGPA, GPA, and MPA/RLV
(Table 3). Most patients with AAV presented with con-
stitutional symptoms. Cutaneous and nervous system
manifestations were most common in patients with
EGPA (71.4% and 92.9%, respectively). Ear, nose, and
throat manifestations and chest manifestations were
characteristic of patients with GPA (84.9% and 66.7%,
respectively). It is noteworthy that ILD is not included
in the BVAS 2003 scoring system. Renal manifestations
developed frequently in patients with MPA/RLV (91.0%)
but also in patients with GPA (63.6%). The mean serum
creatinine level and prevalence of ILD in patients with
MPA/RLV was higher than that in patients with EGPA
and GPA, with a significant difference between MPA/
RLV and EGPA for both (Table 1). Unclassifiable pa-
tients had cutaneous (32.3%), renal (48.4%), and ner-
vous system (48.4%) manifestations (Table 3).Table 2 Surrogate markers in nine patients who were classifie
markers
X-ray evidence of fixed pulmonary infiltrates, nodules, or cavitations present
Bronchial stenosis
Bloody nasal discharge and crusting for 1 month or nasal ulceration
Chronic sinusitis, otitis media, or mastoiditis for >3 months
Retro-orbital mass or inflammation (pseudotumor)
Subglottic stenosis
Saddle nose deformity/destructive sinonasal disease
ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; PR3, proteinase
anti-proteinase-3 antibody-positive patients. bOne patient had bloody nasal dischar
stenosis and saddle nose deformity. cFive patients with chronic sinusitis, three patieDifferences in clinical features between MPO-ANCA-
positive and PR3-ANCA-positive AAV
We compared the demographic and clinical features of
Japanese patients with AAV who had MPO-ANCA and
those who had PR3-ANCA (Table 4). Patients with MPO-
ANCA were significantly older at the time of presentation
(P = 0.012) and had a higher rate of ILD (P = 0.0015). The
mean serum creatinine level was numerically higher in pa-
tients with MPO-ANCA. According to the BVAS 2003
scoring system, MPO-ANCA-positive patients had more
cutaneous (P = 0.046) and renal (P = 0.010) manifestations
and fewer ear, nose, and throat manifestations (P < 0.0001)
with statistical significance.
Of the 33 patients with GPA, 15 patients, 12 patients,
and three patients were positive for MPO-ANCA alone,
for PR3-ANCA alone, or for both ANCAs, respectively,
but three patients were negative for ANCA. Patients with
GPA who had MPO-ANCA had a numerically higher rate
of renal disease (86.7%) than those with PR3-ANCA
(41.7%). The mean serum creatinine level of patients with
MPO-ANCA-positive GPA (2.05 ± 0.35 mg/dl) was also
numerically higher than that of patients with PR3-ANCA-
positive GPA (1.03 ± 0.39 mg/dl).
Clinical features of patients with or without interstitial
lung disease
We compared the demographic and clinical characteristics
of the patients with and without ILD (Table 5). MPO-
ANCA was found significantly more frequently (P < 0.001)
and PR3-ANCA was found less frequently (P = 0.038) in
patients with ILD. These patients also tended to have
more early systemic diseases and less generalised or severe
diseases (P = 0.059) and had significantly lower BVAS (P =
0.019). The mean serum creatinine level and rates of pa-
tients with constitutive symptoms were similar between
the two subgroups. The patients with ILD also had statisti-
cally fewer ear, nose, and throat (P = 0.006) and cardiovas-
cular (P = 0.012) manifestations.d with granulomatosis with polyangiitis using these
Number of patients
(MPO-ANCA/PR3-ANCAa)







-3. aMPO-ANCA/PR3-ANCA, anti-myeloperoxidase antibody-positive versus
ge and crusting and chronic sinusitis, and another patient had subglottic
nts with otitis media, and no patients with mastoiditis.
Table 3 Comparison of disease activity and organ involvement among AAV diseases
EGPA GPA MPA/RLV Unclassifiable
(n = 14) (n = 33) (n = 78) (n = 31)
BVAS 16.1 ± 7.7 19.9 ± 7.4 18.4 ± 7.3 12.1 ± 7.6
General 10 (71.4) 23 (69.7) 56 (71.8) 29 (93.6)
Cutaneousa,b 10 (71.4) 3 (9.1) 16 (20.5) 10 (32.3)
Mucous membranes/eyes 1 (7.1) 8 (24.2) 9 (11.5) 2 (6.5)
Ear, nose, and throata,b,c 6 (42.9) 28 (84.9) 7 (9.0) 1 (3.2)
Chestc 5 (35.7) 22 (66.7) 30 (38.5) 6 (19.4)
Cardiovascular 2 (14.3) 4 (12.1) 6 (7.7) 0 (0)
Abdominal 0 (0) 1 (3.0) 0 (0) 1(3.2)
Renala,b 2 (14.3) 21 (63.6) 71 (91.0) 15 (48.4)
Nervous systema,b 13 (92.9) 14 (42.4) 33 (42.3) 15 (48.4)
Values expressed as mean ± standard error or number (percentage). Disease activity and patterns of organ involvement were defined by the BVAS 2003 scoring
system. AAV, antineutrophil cytoplasmic antibody-associated vasculitis; BVAS, Birmingham Vasculitis Activity Score; EGPA, eosinophilic granulomatosis with
polyangiitis; GPA, granulomatosis with polyangiitis (Wegener’s granulomatosis); MPA, microscopic polyangiitis; RLV, renal-limited vasculitis. Comparisons between
the EGPA, GPA, and MPV/RLV groups were made by Student t test or Mann–Whitney U test. Statistical significance was determined by P < 0.05/3 using Bonferroni
correction: aEGPA versus GPA, bEGPA versus MPA/RLV, cGPA versus MPA/RLV. Unclassifiable AAV was not compared with other forms of AAV.
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This is the first study to apply the EMEA algorithm to
prospectively collected and high-quality data of AAV
patients outside Europe and to elucidate the clinical
phenotypes of the disease. In this study, 156 Japanese
patients with newly diagnosed AAV were enrolled from
major universities and referring hospitals across Japan
and classified according to the EMEA algorithm. The re-
sults clearly indicated that MPO-ANCA-positive MPA/
RLV was the most common form of AAV in the Japanese
population, and more than one-half of the patients with
EMEA algorithm-classified GPA showed MPO-ANCA
positivity. In addition, we showed that ILD was a common
manifestation in Japanese patients with AAV, especially in
those with MPA.
The predominance of MPA/RLV and MPO-ANCA posi-
tivity in the Japanese population is in marked contrast to
the results of studies previously reported from European
countries and the United States [3,17-19]. Watts and col-
leagues validated the EMEA algorithm using 80 paper
cases that were originally written for evaluation of the
BVAS system for systemic vasculitis with some modifica-
tions, representing the relative frequency of AAV in their
communities as follows: GPA >MPA > EGPA [4]. It is
therefore indispensable and important to evaluate the util-
ity of the EMEA algorithm in ethnicities outside Europe,
as we did in this study. We found some difficulties in the
classification between GPA and MPA with the EMEA al-
gorithm; for example, of the nine patients classified as hav-
ing GPA owing to the presence of GPA surrogate markers,
five had chronic sinusitis in which granulomatous inflam-
mation was not proven by histology. Because chronic si-
nusitis is a common disease and because fixed pulmonary
infiltrates and otitis media are sometimes observed inAAV diseases other than GPA, classification of AAV using
GPA surrogate markers should be cautiously applied in
the countries or regions where MPA is more prevalent
than GPA.
Within the spectrum of AAV, there are interesting geo-
graphic differences in the relative incidence of GPA versus
MPA as well as of MPO-ANCA versus PR3-ANCA posi-
tivity [20]. In European countries, the incidence of GPA is
approximately 4.9 to 10 per million, depending on the geo-
graphic location, with higher incidences reported in more
northern countries and lower incidences in more southern
countries [21,22]. A similar inverse relationship between
GPA and MPA has been observed in the Southern Hemi-
sphere [22]. A higher incidence of MPA/RLV than
GPA and the predominance of MPO-ANCA found in the
Japanese and Chinese AAV populations [3,5] could be re-
lated to the lower latitude of these countries.
GPA and MPA are heterogeneous entities with overlap-
ping phenotypes. Recent studies have indicated that the
classification system based on ANCA specificity (that is,
MPO-ANCA versus PR3-ANCA) may better reflect the
phenotypic spectrum of AAV. Cluster analysis of patients
with newly diagnosed GPA and MPA from five clinical tri-
als showed that the ANCA specificity classification may
be more strongly associated with outcomes such as death
and relapse rate than the traditional GPA-MPA separation
[23]. Moreover, compared with the CHCC definition and
the EMEA algorithm, ANCA specificity was more predict-
ive of relapse in patients with biopsy-proven AAV; patients
with PR3-ANCA were almost twice as likely to experience
a relapse as those with MPO-ANCA [24]. In this regard, it
is intriguing that a genome-wide association study of a
European population revealed the presence of genetic dis-
tinctions between GPA and MPA that are associated with
Table 4 Comparison of demographics and disease
manifestations in MPO-ANCA-positive and PR3-ANCA-
positive patients
MPO-ANCA PR3-ANCA P value
(n = 125) (n = 13)
Male/female 47/78 6/7 0.56
Mean (median) age (years) 70.0 ± 1.04 (73) 61.3 ± 3.2 (61) 0.012
Serum creatinine (mg/dl) 1.94 ± 0.17 1.22 ± 0.53 0.19
Interstitial lung disease 57 (45.6) 0 (0) 0.0015
Alveolar haemorrhage 11 (8.8) 1 (7.7) 0.89
Disease severity 0.26
Localised 2 (1.6) 1 (7.7)
Early systemic 33 (26.4) 2 (15.4)
Generalised 68 (54.4) 8 (61.5)




BVAS 17.5 ± 0.71 17.5 ± 2.2 0.99
General 95 (76.0) 10 (76.9) 0.94
Cutaneous 30 (24.0) 0 (0) 0.046
Mucous membranes/eyes 16 (12.8) 4 (30.8) 0.08
Ear, nose, and throat 22 (17.6) 12 (92.3) <0.0001
Chest 49 (39.2) 7 (53.9) 0.31
Cardiovascular 8 (6.4) 2 (15.4) 0.23
Abdominal 2 (1.6) 0 (0) 0.65
Renal 98 (78.4) 6 (46.2) 0.010
Nervous system 55 (44.0) 4 (30.8) 0.36
Values expressed as mean ± standard error or number (percentage) unless
otherwise noted. Five patients who were double-positive for both ANCAs were
excluded from this analysis. ANCA, antineutrophil cytoplasmic antibody; BVAS,
Birmingham Vasculitis Activity Score; MPO, myeloperoxidase; PR3, proteinase-3.
aGeneral performance was categorised according to the World Health
Organization performance status except category 5 (death). bDisease activity and
patterns of organ involvement were defined by the BVAS 2003 scoring system.







(n = 61) (n = 95)
Male/female 28/33 33/62 0.16
Mean (median) age
(years)
69.3 ± 1.6 (71) 67.3 ± 1.3 (71) 0.26
MPO-ANCA 60 (98.3) 70 (73.7) <0.001
PR3-ANCA 3 (4.9) 15 (15.8) 0.038
Serum creatinine (mg/dl) 1.61 ± 0.23 1.83 ± 0.19 0.45
Disease severity 0.059
Localised 1 (1.7) 3 (3.1)
Early systemic 21 (34.4) 15 (15.8)
Generalised 31 (50.8) 60 (63.2)
Severe 8 (13.1) 17 (17.9)
General performancea
0/1/2/3/4 11/25/11/12/2 11/33/17/28/6 0.47
BVASb
BVAS 15.4 ± 1.0 18.4 ± 0.8 0.019
General 49 (80.3) 69 (72.6) 0.27
Cutaneous 13 (21.3) 26 (27.4) 0.39
Mucous membranes/
eyes
5 (8.2) 15 (15.8) 0.17
Ear, nose, and throat 9 (14.8) 33 (34.7) 0.006
Chest 22 (36.1) 41 (43.2) 0.38
Cardiovascular 1 (1.7) 11 (11.6) 0.012
Abdominal 0 (0) 2 (2.1) 0.25
Renal 44 (72.1) 65 (68.4) 0.62
Nervous system 28 (45.9) 47 (49.5) 0.66
Values expressed as mean ± standard error or number (percentage) unless
otherwise noted. ANCA, antineutrophil cytoplasmic antibody; BVAS,
Birmingham Vasculitis Activity Score; ILD, interstitial lung disease; MPO,
myeloperoxidase; MPA, microscopic polyangiitis; PR3, proteinase-3. aGeneral
performance was categorised according to the World Health Organization
Performance Status except category 5 (death). bDisease activity and patterns
of organ involvement were defined by the BVAS 2003 scoring system.
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patients with PR3-ANCA in our RemIT-JAV cohort, we
were not able to perform cluster analysis within this data-
base. We are currently implementing another large-scale
cohort study of Japanese patients with AAV, and the com-
bined database will enable us to clarify an association be-
tween ANCA positivity and clinical characteristics of AAV
in the Japanese population.
MPO-ANCA may contribute to the severity of chronic
renal injury and the prevalence of ILD in patients with
AAV. Studies of renal biopsy specimens from patients
with AAV have demonstrated a higher prevalence and/
or severity of renal lesions in MPO-ANCA-positive pa-
tients compared with PR3-ANCA-positive patients [26].
These reports are in line with our findings that the meanserum creatinine level of MPO-ANCA-positive patients
was numerically higher than that of PR3-ANCA-positive
patients (1.94 versus 1.22 mg/dl).
A number of case reports and small case series have in-
dicated that ILD developed more frequently in patients
with MPO-ANCA-positive AAV, mainly in those with a
diagnosis of MPA, compared with patients with PR3-
ANCA-positive AAV [27,28]. A high ratio of MPO-ANCA
positivity to PR3-ANCA positivity and a high prevalence
of ILD have been reported in Asian countries [8-10], and
vice versa in northern European countries; ILD was re-
ported in 7.2% of all patients with MPA in the United
Kingdom and in less than 10% in other European
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http://arthritis-research.com/content/16/2/R101countries [11,12]. In this study, we confirmed a high
prevalence of ILD in Japanese patients with AAV. These
patients were categorised as having a milder form (that is,
more early systemic and less generalised or severe dis-
eases) and lower disease activity according to the BVAS
(Table 5), partially because ILD is not included in these
definitions. Investigation of the clinical courses and prog-
noses of patients with ILD will shed more light on the
relevance of ILD in the severity and activity of AAV.
We identified 16 unclassifiable AAV patients with ILD
who were eligible for the EMEA algorithm because they
were MPO-ANCA-positive, had symptoms and signs
compatible with AAV such as general symptoms, and
could not be diagnosed as having other diseases. A pre-
vious study reported that MPO-ANCA seroconversion
from negative to positive occurred in 10% of patients
with ILD in their clinical courses and that some patients
with MPO-ANCA and ILD eventually developed typical
MPA [29]. On the other hand, vasculitis was proven in
five of 15 biopsy specimens of MPO-ANCA-positive pa-
tients with pulmonary fibrosis [13]. These data indicate
that patients with unclassifiable AAV and ILD could be
classified as having MPA. Further investigation is re-
quired to pursue this possibility.
This study has some limitations. The number of pa-
tients evaluated was limited, and the patient data were
collected from the university and referral hospitals in
large cities in Japan, which might cause tertiary care
biases for the relative frequency of AAV diseases.
Conclusions
MPO-ANCA-positive MPA/RLV is the most common
component of AAV in the Japanese population, and more
than one-half of patients with GPA are also positive for
MPO-ANCA. ILD is an important clinical manifestation
in Japanese patients with AAV. Unclassifiable vasculitis
with MPO-ANCA positivity and ILD may represent a
novel variant of MPA. These data confirm the substantial
difference in clinical and ANCA serological features of
AAV between western countries and Asian countries, in-
cluding Japan, and indicate that further investigation and
discussion are required from a global perspective for a bet-
ter AAV classification system that can be applied to all
geographic areas and ethnicities.
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